Free Trial

Astellas Pharma (ALPMY) Insider Trading & Ownership

Astellas Pharma logo
$11.66
-0.02 (-0.17%)
(As of 11/1/2024 ET)

There is no recent insider trading on record for Astellas Pharma, but the stock has been recently traded by U.S. Congress members, who may have more information about the industry than the general public.

Get ALPMY Insider Trade Alerts

Want to know when executives and insiders are buying or selling Astellas Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Astellas Pharma Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellAverage Share PriceTotal Transaction
7/10/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Sell$14.40$15,001 - $50,000
2/27/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Buy$14.09$15,001 - $50,000
1/13/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Sell$14.62$1,001 - $15,000
(Data available from 1/1/2013 forward)

Astellas Pharma Key Executives

  • Mr. Naoki Okamura BSc (Age 62)
    President, CEO & Director
    Compensation: $1.96M
  • Mr. Atsushi Kitamura
    Senior Executive Officer & CFO
  • Nobue Yasuda
    General Manager of Finance & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Senior Managing Executive Officer
  • Ms. Catherine B. Levitt
    General Counsel
  • Mr. Katsuyoshi Sugita (Age 57)
    Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
  • Mr. Stig Ogata
    Vice President of Corporate Communications
  • Ms. Tatjana Dragovic
    Senior VP and Head of Ethics & Compliance
  • Mr. Nobuaki Tanaka
    President of Japan Commercial & Senior Corporate Executive
  • Jun Kono
    Senior Executive Officer & Head of Japan Commercial


This page (OTCMKTS:ALPMY) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners